Skip to content
Aussie8 – Lifestyle
Author:
Mwyngil Therapeutics
Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.
June 25, 2026